Emerging therapies for AMD management

Video

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

Anat Loewenstein, MD, chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD.

See more AMD Awareness content here, here, and here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
A close up of an eye with a brown iris, concept image for diabetic retinopathy and glaucoma research. Image credit: ©Made in Uruguay from Pexels – Canva.com

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001

Sydney M Crago
July 9th 2025
Article

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The International Space Station (ISS) pictured in orbit above Earth. Concept image for International Spectralis Symposium conference meeting in Heidelberg, Germany, and NASA. ©Paopano – stock.adobe.com

Long-duration spaceflight tests the limits of telemedicine

Sheryl Stevenson;Steven Laurie, PhD
July 3rd 2025
Article

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

European Commission grants label extension for Eylea 8 mg with extended 6-month treatment interval

Martin David Harp
June 30th 2025
Article

With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.

An illustration of an eye with computer chip in the iris. Concept image for artificial intelligence (AI), AI-READI project, fluorescence lifetime imaging ophthalmoscopy (FLIO) and retinal imaging. Image credit: ©okalinichenko – stock.adobe.com

The significance of FLIO in diabetic eye disease

Aaron Y. Lee, MD, MSCI;Sheryl Stevenson
June 23rd 2025
Article

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

© 2025 MJH Life Sciences

All rights reserved.